Analysis of Molecular Imaging Biomarkers Derived from [[sup.18]F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis Predicts Overall Survival in Patients Undergoing [[sup.225]Ac]Ac-PSMA-617-Augmented [[sup.177]Lu]Lu-PSMA-617 Radioligand Therapy

• Published in: Cancers 2024-10, Vol.16 (20)
• Main Authors: Burgard, Caroline, Khreish, Fadi, Dahlmanns, Lukas, Blickle, Arne, Bastian, Moritz B, Speicher, Tilman, Maus, Stephan, Schaefer-Schuler, Andrea, Bartholomä, Mark, Petto, Sven, Ezziddin, Samer, Rosar, Florian
• Format: Article
• Language: English
• Subjects: Biological markers; Health aspects; Methods; Patient outcomes; Prostate-specific antigen; Radiotherapy
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16203532

Augmentation of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) by alpha emitting [sup.225] Ac, known as the tandem therapy concept, is a promising escalating treatment option in patients with advanced metastatic castration-resistant prostate cancer (mCRPC). The aim of this study was to analyze the value of imaging parameters in baseline [[sup.18] F]FDG PET/CT for predicting response and outcome to PSMA tandem RLT in patients with insufficient response to the initial [[sup.177] Lu]Lu-PSMA-617 monotherapy. The quantitative whole-body imaging biomarker total lesion glycolysis (TLG) was identified as a prognostic biomarker for overall survival (OS), while response could not be predicted by any of the tested parameters. Using [[sup.18] F]FDG PET/CT in clinical practice could help predict outcomes and may provide more personalized care for mCRPC patients.